Before initiating Exkivity, evaluate QTc and electrolytes and correct abnormalities in sodium, potassium, calcium, and magnesium .
Select patients with locally advanced or metastatic NSCLC for treatment with Exkivity based on the presence of EGFR exon 20 insertion mutations .
The recommended dosage of Exkivity is 160 mg orally once daily until disease progression or unacceptable toxicity. Take Exkivity with or without food , at the same time each day.
Swallow Exkivity capsules whole. Do not open, chew or dissolve the contents of the capsules.
If a dose is missed by more than 6 hours, skip the dose and take the next dose the following day at its regularly scheduled time.
If a dose is vomited, do not take an additional dose. Take the next dose as prescribed the following day.
Exkivity dose reduction levels for adverse reactions are summarized in Table
1. Recommended dosage modifications of Exkivity for adverse reactions are provided in Table 2.
Moderate CYP3A inhibitor cannot be avoided, reduce the Exkivity dose by approximately 50% .Exkivity at the dose taken prior to initiating the moderate CYP3A inhibitor.
Reduce the Exkivity dose by approximately 50%.
from FDA,2023.09
Exkivity is a targeted drug for the treatment of specific types of non-small cel···【more】
Release date:2024-08-07Recommended:139
Exkivity is an oral capsule drug primarily used for the treatment of patients wi···【more】
Release date:2024-08-07Recommended:140
Exkivity is an innovative, oral, small molecule tyrosine kinase inhibitor (TKI) ···【more】
Release date:2024-08-07Recommended:150